Neuropathic pain, a maladaptive and chronic condition that can develop after a lesion or disease affecting the somatosensory system, is characterized by allodynia, hyperalgesia and spontaneous pain, and comorbidities such as sleep deprivation, depression and anxiety. The activation of microglial cells in response to nerve injury has been implicated in the development of neuropathic pain. Mediators such as Neuregulin-1, matrix metalloproteinase (MMP)-2, MMP-9, The chemokine (C-C motif) ligand 2 (CCL2) and fractalkine are released after nerve injury and are involved in the activation of microglial cells. These activated cells in turn release factors that increase the excitation and decrease the inhibition of interneurons. Microglial cells release factors such as interleukin (IL)-6, IL-1b and tumour necrosis factor-a (TNF-a) that cause the painful symptoms. It is becoming increasingly apparent that an intricate network of cytokines and cellular signalling mechanisms underpin the complex relationship between microglia and various cell types including neurones, astrocytes, oligodendrocytes, mast cells and T-cells. Although the precise mechanism of action of microglial cells in producing neuropathic pain has not been completely elucidated, research into these different activating factors and cytokines is providing further insight into the role of microglial cells in the development and maintenance of neuropathic pain. Further studies also are required to elucidate how "pain" mediators act on neurones and how the interactions between these mediators, or between neurones and glia in the presence of these mediators occur, in order to develop effective therapies for the management of neuropathic pain.
includes tricyclic antidepressants, pregabalin and gabapentin. 5 These treatments do not target the underlying mechanisms causing the pain and are not specific to the different phases in the development of neuropathic pain. 6 Recent research has shown that microglia play an important role in initiating, sustaining and mediating the neuropathic pain. This review was completed using a systematic approach, with predetermined inclusion and exclusion criteria. The databases EMBASE and Medline were searched extensively for relevant papers published in English between the yr 2000 -2016. The search terms "microglial" were combined with each of the following terms: "neuropathic pain" or "cytokine". Here, we summarised the literature as a narrative review and provide a critical insight into the understanding of the role of microglial cells in neuropathic pain.
Microglia activation in neuropathic pain
Microglial cells are quiescent immune cells of the central nervous system. 4 When microglial cells are activated, these cells develop the ability to phagocytose, present antigens to T lymphocyte cells and release cytokines. 4 After nerve injury, molecules released from neurones contribute to microglial activation, causing changes in morphology, migration to the site of injury and increased proliferation 7 8 (Fig. 1 ). This reaction of microglial cells to nerve injury is termed microgliosis. After mokines, nucleotides, and other pro-inflammatory mediators released from damaged afferent terminals could signal through post-synaptic surface receptors to activate microglia. Preclinical studies showed spinal nerve injury could lead to sustained neuronal upregulation and/or increased synaptic release of neuregulin-1, matrix metalloproteases, chemokine (C-C motif) ligand 2, fractalkine and its cognate receptor CXCR3. Release of danger/damage-associated molecular patterns (DAMPs), intracellular nucleotides or proteins that become highly immunogenic when liberated into extracellular space, could also occur in primary afferent injury. In particular, ATP signalling through ionotropic purinergic receptor (P2X4R and P2X7R) was shown to contribute to microglial activation and inflammatory cytokine release. Activation of microglial pattern recognition receptors (PRRs), for example toll-like receptors (TLR2 and TLR4) and receptor for advanced glycation end products (RAGE), by afferent-derived DAMP mediator high mobility group box protein 1 (HMGB1), represents another microglial activation pathway.
Activated microglia will in turn release pro-inflammatory cytokines (TNF-a, IL-1b and IL-6), colony-stimulating factor 1 (CSF1), brain-derived neurotropic factor (BDNF), reactive oxygen species (ROS) among others into the spinal cord micro-environments, to direct multidirectional crosstalk between primary afferent, interneurons, secondary neurones, astrocytes and microglia.
peripheral nerve injury, microglia within the spinal cord are activated and undergo significant morphological changes, including demonstrating an increased expression of microglial markers including CD11b and Iba1. 9 Murine models of neuropathic pain have also indicated spinal cord proliferation of microglial cells after peripheral nerve injury. 10 11 9 In addition to the important morphological changes that occur after nerve injury, there are also significant biochemical alterations. Nerveinjury induced microglial activation results in a significant increase in ATP receptor P2X4 expression, and chemokine receptor CX3CR1 in spinal cord microglia. [12] [13] [14] Furthermore, administration of P2X4 and CX3CR1 antagonists results in an attenuation of nerve injury-induced neuropathic pain, demonstrated by a reduction in mechanical allodynia. 12 14 In addition, nerve injury has also been shown to cause the phosphorylation of p38 mitogen-activated protein kinase (MAPK) in spinal cord microglia. 15 16 Whilst spinal nerve ligation causes a significant increase in phsopho-p38 (p-p38) concentrations, non-injured rats have very low concentrations of p-p38. P38 is almost exclusively expressed by spinal cells that express microglial markers CD11b/OX-42 and Iba1, whilst intrathecal administration of a p38 inhibitor substantially reduces nerve injury-induced mechanical allodynia. 17 18 These are a few of the possible nerveinjury induced microglial biochemical alterations that may be involved in the generation and maintenance of neuropathic pain. Despite the unclear mechanism of action by which microglial cells cause neuropathic pain, several studies have shown that inhibiting microglial activation reduces hyperalgesia and allodynia after nerve damage. 8 15 19 Inflammatory mediators and microglia interaction in neuropathic pain
Evidence suggests that neuropathic pain is the result of neuroimmune interactions after nerve injury. Several signalling pathways have been identified between the injured primary afferent neurone and microglial cells, including Neuregulin, erb, matrix metalloproteinases and chemokine-mediated pathways. 7 There is a complex interaction between factors that result in the activation of microglial cells, whilst activated glial cells subsequently release mediators, such as tumour necrosis factor and various proinflammatory interleukins, which result in the generation and maintenance of neuropathic pain.
Neuregulin-1 and microglia interaction
One of the key signalling pathways between neurones and microglial cells is via neuregulin-1, which is a growth factor involved in neuronal development. 7 Calvo and colleagues 7 demonstrate that neuregulin-1 is released from primary afferent nerves after spinal nerve ligation in rats. Furthermore, the receptors for neuregulin-1, which are erbB2, 3, and 4, are present on the surface of microglial cells, suggesting an interaction between neurones and microglial cells. 7 Calvo and colleagues found that blocking erbB2 specifically reduced proliferation and activation of microglia after spinal nerve ligation. 7 This is supported by Xiang and colleagues 20 , who used mice to detect an increase in neuregulin-1 after injury, and increased activity of the erbB2 receptor. Calvo and colleagues 21 concluded that neuregulin-1-mediated erbB2 activation resulted in the stimulation of the MEK/ERK pathway in microglial cells. 21 ERK is an extracellular signal-regulated kinase belonging to the mitogenactivated kinase (MAPK) family. 21 The MEK/ERK pathway stimulates proliferation of microglial cells, and the release of other pro-inflammatory mediators. These studies suggest that neuregulin-1 and erbB2 could potentially be targeted to treat neuropathic pain.
Matrix metalloproteinase and microglia interaction
Microglial cells are also activated through neuronally derived matrix metalloproteinase-9 (MMP-9). 7 In a spinal nerve ligation model by Kawasaki and colleagues 22 , the authors found an increase in MMP-9 shortly after nerve injury in the injured dorsal root ganglion primary sensory neurones. Moreover, treatment with an MMP-9 inhibitor delayed the onset of neuropathic pain for 11 days, suggesting that MMP-9 is involved in the initiation of neuropathic pain rather than maintenance of the pain. 22 Liou and colleagues 23 used a peripheral partial sciatic nerve lesion to demonstrate that MMP-9 concentrations increased immediately after the nerve injury and returned to control concentrations within two weeks, supporting Kawasaki's discovery that MMP-9 is involved in the development of neuropathic pain. This theory was further supported by Rojewska and colleagues 24 who demonstrated an upregulation of MMP-9 after nerve injury using a chronic constriction injury mouse model. In addition, minocycline, an antibiotic that has been suggested as a potential therapeutic option for the treatment of neuropathic pain, decreased the concentrations of MMP-9 after nerve injury. 24 As MMP-9 is involved in the development of pain, minocycline treatment would be the most beneficial when given before the development of pain, or in the initial stages of pain. Matrix metalloproteinase-2 (MMP-2) has also been implicated in neuropathic pain. Unlike MMP-9, MMP-2 has been associated with the maintenance of neuropathic pain rather than the initiation. 25 Using a model of spinal nerve ligation, Kawasaki and colleagues 22 found that MMP-2 upregulation occurred at day seven and was still present on day 21. Administration of an MMP-2 inhibitor partially decreased allodynia on day one and resulted in almost complete attenuation of allodynia by day 10. 22 Kawasaki and colleagues 22 concluded that MMP-2 is involved in the persistence of neuropathic pain through IL-1b cleavage, as MMP-2 null mice had lower concentrations of cleaved IL-1b. Liou and colleagues 23 support these findings through their study with partial sciatic nerve ligation, in which MMP-2 concentrations increased gradually after injury. Furthermore, intrathecal injection of MMP-2 caused neuropathic pain in mice, whilst peritoneal administration of GM6001, a general inhibitor of MMP, significantly attenuated thermal hyperalgesia and tactile allodynia induced by nerve injury. 23 Therefore, both MMP-9 and MMP-2 seem essential for the development and maintenance of chronic neuropathic pain, as these metalloproteinases are involved specifically in the initiation and the persistence of neuropathic pain, respectively.
The chemokine (C-C motif) ligand 2 and microglia interaction
Signalling between neurones and microglial cells also involves The chemokine (C-C motif) ligand 2 (CCL2), also known as monocyte chemoattractant protein 1 or MCP-1. 7 CCL2 has low expression under normal conditions but is upregulated after nerve injury. 26 CCL2 binds to the CCR2 G-protein coupled receptor present on microglial cells. 27 Thacker and colleagues 27 29 found that intrathecal injection of CCL2 rapidly resulted in thermal hyperalgesia and mechanical allodynia. However, these effects lasted for only four days, suggesting that CCL2 may be involved in initiating neuropathic pain rather than maintaining the pain. 29 Similarly to the other studies mentioned, Dansereau and colleagues 29 demonstrated that inhibiting CCL2 activation of CCR2, using a selective CCR2 antagonist, resulted in the inhibition of neuropathic pain symptoms, namely thermal hyperalgesia and sustained mechanical hyperalgesia (up to four consecutive days). These studies show an increased concentration of CCL2 after nerve injury, and a decrease in neuropathic pain when CCL2 is inhibited, indicating a relationship between CCL2 release and neuropathic pain through increased excitation of neurones, and activating microglial cells.
Fractalkine and microglia interaction
The chemokine fractalkine has also been implicated in the activation of microglial cells after nerve injury. 14 Fractalkine is present on the surface of neurones and can be cleaved from the neurones as a result of increased neuronal activity. 4 Fractalkine can be cleaved by the protease Cathepsin S (CatS), which is released by activated microglial cells, creating a positive feedback loop for the activation of microglial cells. 14 30 The cleaved fractalkine binds to the CX3CR1 receptor present on microglial cells, resulting in activation of the microglial cell. 7 tion in rats to demonstrate increased concentrations of fractalkine after nerve injury. CX3CR1 activation by fractalkine resulted in activation of the ERK5 pathway, a member of the MAPK family also implicated in neuropathic pain by neuregulin-1, which resulted in hyperalgesia and pain hypersensitivity. 31 Knockdown of ERK5 resulted in decreased pain, thus implicating ERK5 as an initiator of neuropathic pain. 31 Calvo and colleagues 32 was the only study to also look at cold allodynia. These studies have all used mice or rat models and thus further research is necessary to translate this knowledge to humans. These studies indicated that a variety of mediators are involved in the development of neuropathic pain after nerve injury, thus suggesting that the underlying mechanism behind chronic neuropathic pain is a complex interaction of factors. These studies do not look at the interactions between different factors that can activate microglial cells. As activation of microglial cells does not happen in isolation with only one mediator present, more research is required to create a temporal map of mediators present after nerve injury that result in microglial activation.
Resting microglial cells have small cell bodies and long, branched processes. 33 As microglial cells are activated, the cells undergo morphological changes in which the cell body becomes relatively large and the processes become shorter. 34 These activated microglial cells, also called amoeboid microglia, have higher rates of migration, proliferation and phagocytic behaviour. 34 New markers appear on the surface of activated microglial cells, allowing for the detection of microglial activation. 25 These markers are type 3 complement receptor (CR3), cluster of differentiation 11b (CD11b), cluster of differentiation 14 (CD14), ionized binding calcium adapter protein and toll-like receptor 4 (TLR4). 4 Activation of the p38 mitogen activated protein kinase (MAPK) pathway is also present with microglial activation and can be detected. 4 Mika and colleagues 35 used C1q and OX42
antibodies, which bind to CD11b, to label microglial cells to examine microglial activation after nerve injury. Using a model of chronic constriction injury of the sciatic nerve in mice, Mika and colleagues 35 found microglial activation to start on day two after the injury, with a peak on day seven to nine and a slow decline in both neuropathic pain symptoms, such as tactile and cold hypersensitivity, and microglia activation from day 17 -21. This timeframe for microglial activation is comparable with Obata and colleagues 36 who observed microglial activation through OX-42 at day 3 after injury, though Obata and colleagues did not examine the decrease in microglial activation over time. On the other hand, Tanga and colleagues 37 examined microglial activation using real time PCR identification of CD14 and TLR4 and found a peak at day four and a return to normal by day 28. Therefore, the precise timeframe of microglial activation after nerve injury is not certain, and the temporal expression of surface markers on the activated microglial cells. These studies suggest that microglial activation is mainly important in the initial stages of neuropathic pain, as microglial levels return to control levels within a month while pain persists. Therefore, studies need to be conducted in order to determine how pain is maintained after the reduction in microglial activation.
Cytokines and microglia interaction in neuropathic pain
When microglial cells are activated, these cells release a plethora of mediators that have been implicated in neuropathic pain.
Tumour necrosis factor-a and microglia interaction
Tumour Necrosis Factor a (TNF-a), released by microglial cells after activation of Toll Like Receptor 3 and Toll Like Receptor 4, increases postsynaptic currents and results in an increase of synaptic transmissions. 7 Using a chronic injury rat model, Lee and colleagues 38 discovered increased concentrations of TNF-a one day after injury, with a peak at day three and a decrease to control concentrations by day seven. Pain hypersensitivity, as evidenced through behavioural analysis, was still present 28 days after injury, when TNF-a concentrations had decreased to control, suggesting that TNF-a is involved in the onset of neuropathic pain rather than persistence of neuropathic pain. 38 Youn and colleagues 39 demonstrated a quick onset of thermal hyperalgesia (30 min) with a more delayed onset of mechanical allodynia (two h) after TNF-a administration in rats. These effects were limited by administration of a TNF-a antagonist. 39 Zhang and colleagues 40 support the observations that intrathecal TNF-a induces heat hyperalgesia. Zhang and colleagues 40 examined the relationship between TNF-a, TNF receptor 1 (TNFR-1) and TNF receptor 2 (TNFR-2) using TNFR-1 and TNFR-2 knockout mice, and TNFR1/R2 double knockout mice. Heat hyperalgesia was reduced in both TNFR-1 knockout mice and TNFR-2 knockout mice, whereas double knockout mice did not develop any heat hyperalgesia, indicating that both receptors are required for the full expression of neuropathic pain. 40 Zhang and colleagues 40 suggest that TNF-a stimulates the development of neuropathic pain through increased glutamate release from presynaptic neurones, resulting in increased activation of NMDA receptors.
Interleukin 1b and microglia interaction
Interleukin 1b (IL-1b) is a small pro-inflammatory cytokine released by activated microglial cells. 41 IL-1b is present at low concentrations under physiological conditions in the spinal cord and is upregulated after nerve injury. 41 IL-1b is believed to stimulate the development of neuropathic pain by acting directly on neurones, and stimulating the release of other proinflammatory mediators to produce an indirect effect. 41 Gabay and colleagues 42 used partial nerve injury and complete nerve ligation in mice to investigate the effect of a IL-1 receptor antagonist (IL-1ra) on the development of neuropathic pain. Mice that were not treated with IL-1ra developed allodynia and increased ectopic activity after nerve injury, whereas IL-1ra mice did not develop allodynia and did not have increased ectopic activity, thus implicating IL-1b in the development of neuropathic pain, as evidenced by the development of hyperalgesia, allodynia and behavioural changes such as autotomy. 42 Lee and colleagues 43 used a chronic injury rat model to investigate the temporal expression of IL-1b, demonstrating increased concentrations on day one after injury, with elevated concentrations persisting until day seven and a return to control by day 14. This suggests that IL-1b is involved in the initiation of chronic neuropathic pain. 43 Kawasaki and colleagues 38 used patch clamp recordings to show that IL-1b reduced inhibitory postsynaptic currents, and increased spontaneous excitatory postsynaptic currents, thus contributing to neuropathic pain symptoms by sensitizing the neurones.
Interleukin 6 and microglia interaction
Interleukin 6 (IL-6) is a cytokine released by activated microglial cells in response to nerve injury. 43 Lee and colleagues 43 discovered an increase in IL-6 one day after nerve injury, which remained elevated at day 28, with a peak at day seven. This suggests that IL-6 is involved in maintenance of neuropathic pain, indicated by the development of pain behaviour such as hyperalgesia and allodynia, as elevated IL-6 concentrations persist after TNF-a and IL-1b have both returned to control concentrations. Zanjani and colleagues 44 found elevated concentrations of IL-6 in mice with chronic constriction injury. Latremoliere and colleagues 45 suggest that IL-6 plays a role in microglial activation, as IL-6 deficient mice had altered microglial activation. In addition, Latremoliere and colleagues 45 also demonstrated the presence of IL-6 before microglial activation, with increased concentrations of IL-6 after microglial activation. These results suggest a positive feedback loop between IL-6 and microglial cells, allowing for more mediators to be released and more neuropathic pain symptoms to be present. 45 Interaction between microglia and other cell types in neuropathic pain
Evidence discussed so far gives credence to the notion that microglial cells may directly contribute to neuronal excitability and, therefore, influence and co-ordinate the activity of neuronal networks. Their abnormal activation in disease states, however, causes maladaptive, sensitised neuronal-glial circuits to develop. In addition, activated microglial cells have been shown to interact with many cell types, thus further disrupting neuronal homeostasis and ultimately culminating in the expression of neuropathic pain (Fig. 2) 
Interaction between microglia and neurones
There is mounting evidence to indicate that this "cross-talk" between neurones and microglia is fundamental in the development of neuropathic pain-related behavioural symptoms and spinal dorsal horn plasticity. A recent study using a rat model of spinal nerve ligation-induced neuropathic pain examined the effect of combining tramadol with minocycline, 46 a tetracycline antibiotic that has been shown to relieve neuropathic pain through microglial inhibition, as indicated by attenuation of nociceptive behaviours. 47 48 Combination therapy exhibited synergistic, dose-dependent antiallodynic effects that were more significant than with either tramadol or minocycline therapy in isolation. 46 These findings were paralleled with the observation that suppression of Fos and OX42 expression, markers of activated neurones and microglia respectively, was greater compared with that seen with either drug administered alone. 46 These findings build on earlier observations that modulating microglial activity using minocycline can augment the efficacy of morphine-induced analgesia, 49 50 implying that a bilateral interaction between neurone and glia exists. Breaking this interaction may represent a novel therapeutic, opioid-sparing strategy to ameliorate the symptoms of neuropathic pain.
Other studies have used alternative approaches to investigate the microglia-neurone interaction. In a cleverly designed study, Coull and colleagues 51 proved the importance of brainderived neurotrophic factor (BDNF), shown to be released from microglia after their stimulation by ATP, as a crucial signalling molecule between microglia and neurones. ATP-stimulated release of BDNF from microglia was shown to mimic the shift in neuronal anion gradient, E(anion), that has been shown to underlie neuropathic pain after peripheral nerve injury. 52 Both preventing BDNF release, and interrupting signalling between BDNF and its receptor, diminished allodynia and the effect on E(anion). 51 Further corroborating evidence implicating BDNF has been shown very recently in studies exploring the impact of exercise therapy on neuropathic pain, 53 54 after findings that suggest physical exercise can alleviate neuropathic pain symptoms such as thermal and tactile hyperalgesia and allodynia. 55 In a mouse model subjected to partial ligation of the sciatic nerve, physical training in the form of a five-week aerobic swim exercise program reversed mechanical hypersensitivity, normalised BDNF upregulation and reversed microglial hyperactivity; crucially, all these effects persisted after exercise cessation. 54 The reported effect of exercise may therefore, at least in part, be as a result of modulation of neurotrophins which are released from microglia.
Armed with this growing appreciation of microglial involvement in the pathophysiology of neuropathic pain, a recent interesting study looked at the influence of some of the current therapies used on microglia activation in a chronic constriction injury rat model.
56 Of all the drugs tested, fluoxetine yielded the strongest analgesia and was also the only one to downregulate IBA-1 protein concentration, used as a marker for microglia and macrophages, 56 in both the lumbar spinal cord and dorsal root ganglion. Such evidence suggests that strategies targeting more specific inhibition of microglia may be promising in the therapeutic management of neuropathic pain. However, other research suggests that it may not be as simple as "blanket-blocking" microglial activation, as there is greater complexity to the relationship between microglia and neurones. Microglial activation has been shown to be a polarised process, 57 58 split into two phases where microglia can exhibit two phenotypes that have opposing effects on surrounding structures -the rapidly induced pro-inflammatory M1 phase and the relatively smaller and transient anti-inflammatory M2 phase. 59 The latter involves the release of anti-inflammatory cytokines, such as IL-10 and tissue inhibitor of metalloproteinases (TIMP) , 60 which promote repair of tissue. Therefore, it may be prudent to adopt a more refined approach in order to exploit the interaction between microglia and neurones for the biggest benefit by specifically attenuating a prolonged M1 state and/or shifting microglia towards M2 polarisation. Popiolek-Barczyk and colleagues 60 very recently demonstrated that parthenolide (PTL), a naturally occurring compound shown in patients to relieve migraine, 61 relieves neuropathy symptoms (both allodynia and hyperalgesia) in a rat model of neuropathy. Although an overall increase in Iba-1 protein concentration was demonstrated, further analysis showed that overall protein concentrations of M1 phase factors were reduced, whilst M2 factors were increased. 60 These findings have enlightened and deepened our understanding of the complex, intricate relationship between microglia and neurones, but much remains to be understood. Indeed, this hard truth is best illustrated by the presence of conflicting evidence. For example, whilst Nazemi and colleagues 62 demonstrated suppression of thermal hyperalgesia, microglial activation, spinal cord TLR4 expression and wide dynamic range neurone discharge with repeated administration of minocycline post-injury (i.e. from six days post-surgery) in a chronic constriction injury rat model, Yamamoto and colleagues 63 found that starting minocycline seven days after surgery did not prevent nerve injury-induced microglial activation, convergent nociceptive inputs, or tactile and thermal hypersensitivity, although a different model was used. Thus, variations in methodology and models of neuropathic pain make interpretation of conclusions difficult. More focused research is warranted to further delineate and target neurone-microglia interactions, in order to elucidate novel, feasible strategies to combat neuropathic pain.
Interaction between microglia and astrocyte
Along with microglia, astrocytes are another glial cell-type whose contribution to neuropathic pain development is increasingly being recognised. It is becoming apparent that there are complex interactions between different aspects of the neural immune system, involving a multi-faceted network of signalling pathways mediated by multiple chemokines. Bian and colleagues 64 demonstrated an example of how such signalling may operate between astrocytes and microglia. Using tetanic stimulation of the sciatic nerve (TSS) in a rat model, it was shown that interleukin-23 (IL-23) and its receptor, expressed on astrocytes, are crucial for the development of allodynia, whilst IL-23 inhibition relieved allodynia and suppressed the expression of glial fibrillary acidic protein (GFAP), an astrocyte marker. Interestingly, there was a simultaneous increase observed in IL-18 and its receptor (IL-18R), and CX3CL1 and its receptor (CX3CR1), after TSS. 64 Furthermore, IL-18 was exclusively produced by microglia, whilst IL-18R was localised on astrocytes. Although CX3CR1 was expressed purely in microglia, CX3CL1 was produced in both neurones and astrocytes. Bian and colleagues 64 subsequently proved that the upregulation of IL-23 after TSS is mediated by CX3CL1 and IL-18 signalling, as inhibition of CX3CL1 and IL-18 suppressed IL-23 upregulation and attenuated TSS-induced allodynia. This builds on previous evidence revealing the importance of IL-18 signalling in neuropathic pain. Miyoshi and colleagues 65 demonstrated that nerve injury induced a striking increase in IL-18 and IL-18R expression in hyperactive microglia and astrocytes, respectively, causing NFjB activation in spinal astrocytes via stimulation of IL-18R, thus inducing astrocytic hypertrophy and the subsequent release of pro-inflammatory molecules (IL-1b, IL-6, TNF-a) that sensitise dorsal horn neurones in the spinal cord. Thus, there appears to be evidence of intricate communication between astrocytes, microglia and neurones, mediated through multiple cytokines, which underlie neuropathic pain development.
As discussed earlier, it is now known that microglia do not constitute a homogenous cell population, but rather can display a range of phenotypes. Whether they adopt a form that exacerbates tissue injury or promotes repair likely depends on the nature of signalling within their microenvironment. Tanuma and colleagues 66 showed that chemokines released from astrocytes, in particular CCL2 and CXCL10, influence the activation of microglia as effector cells in demyelinating lesions, as seen in conditions such as multiple sclerosis. A recent study by Batlle and co-workers 67 examined the relationship between microgliosis and astrogliosis in an in vivo model of hippocampal excitotoxic injury. NMDA injection, within 38 days, triggered atrophy, neuronal loss, and fast astroglia-mediated S100B increase. S100B is released by astrocytes constitutively 68 and has been suggested to have neuroprotective properties. For example, Reali and colleagues 69 demonstrated that S100B prevented trimethyltin-induced changes, specifically showing that S100B attenuated trimethyltin-induced increase in TNF-a expression in microglia. Batlle and colleagues 67 further proved the importance of astrocytic S100B as a key modulator of microglia phenotype, as co-injection of NMDA with L-a-aminoadipate, a toxin inducing temporary astroglial ablation, produced a striking maintenance of neuronal death associated with enhanced microglial reaction and proliferation. Hence, the interplay between astrocytes and microglia may determine the phenotype that microglia adopt after nerve injury or neurodegeneration. Despite these findings, however, there remains much ambiguity as to whether astrocytes and microglia may interact to contribute towards the development of neuropathic pain. Again, variation in study design can result in conflicting evidence that complicates and clouds our understanding. For example, although evidence has been presented to suggest microglia are involved in the earlier phase of neuropathic pain development compared with astrocytes, in a rat model of bone cancer pain, there was delayed microglial activation on days 14 and 21, but not day seven, whereas astrocytic activation was rapid and persistent from day seven to 21. 70 In addition, minocycline had no effect on neuropathy symptoms in the first week, but did after 14 days. 70 In addition, there is also evidence in chemotherapy-induced neuropathic pain models indicating that astrocytic activation contributing to allodynia is independent of microglial activity. 71 72 Interaction between microglia and epithial cells
Although there is significant evidence for the role of activated spinal microglia in mediating neuropathic pain, the precise role of peripheral inflammation in activating neuronal microglial cells, and whether the structure and function of the blood-brain barrier (BBB) play a significant role, remain to be elucidated. The BBB is a dynamic and functional structure that separates the central nervous system from the systemic circulation, whose morphology and function can be affected and disrupted by neurological diseases such as meningitis/encephalitis, traumatic brain injury and small vessel disease. 73 More recently, there has been accumulating evidence that inflammatory pain states produce significant changes in the BBB. 74 75 Huber and colleagues 74 first demonstrated that inflammatory-mediated pain mediates both the functional and molecular properties of the BBB, specifically by altering permeability and tight junctional protein expression. Intracellular adhesion molecule-1 (ICAM-1) is a key component of the BBB. 76 The repeatedly observed correlation between induction of ICAM-1 and increased permeability of the BBB 77 suggests that ICAM-1 plays a major role in cell-to-cell adhesive interactions and provides opportunity for entry of immune cells into the CNS. Furthermore, another positive correlation that has been observed is between ICAM-1 expression and activated microglia, in the context of cerebral inflammation. 78 79 A followup study by Huber and colleagues 80 examined the effects of k-carrageenan-induced inflammatory pain (CIP) on BBB expression of ICAM-1, in tandem with examining microglial activation in the brain. CIP induced a biphasic response in ICAM-1 protein expression, suggesting different mechanisms of activation between early and delayed phases. In conjunction with this, early microglia activation was observed but no increase in peripheral pro-inflammatory cytokine concentrations were seen until six h. In addition, immunohistochemistry showed that activation of ICAM-1 was specific to regions that directly correlated with increased expression of activated microglia. Overall, these findings provide some basis for arguing that the initial effects on the blood-brain barrier after central inflammatory pain may be mediated through activated microglial cells in the brain. 80 
Interaction between microglia and oligodendrocyte
Whilst there has been significant interest in the role of the neural immune system, relatively little emphasis has been placed on the role of neuropathic pain in mediating other elements of the central nervous system. Oligodendrocytes are a crucial element of the central nervous system whose primary role is to generate myelin for axonal insulation. Whilst their role in the pathophysiology of various neuro-psychiatric disorders, most notably multiple sclerosis, is well known, whether function or pathology is linked with the development of neuropathic pain remains to be elucidated. Some initial investigations have recently been conducted to address this question. Gritsch and colleagues 81 used a wellestablished method of specifically ablating oligodendrocytes using diphtheria toxin (DTX) in mice and demonstrated that treated mice developed cold (but not heat) allodynia at five days, followed by mechanical hypersensitivity at 12 days post DTX, both of which were not observed in control mice. Further analysis with reverse transcription-PCR, immunohistochemistry and electron microscopy proved oligodendrocyte loss and dysfunction in the spinal cord. Interestingly, immunohistochemistry studies to trace the activity of microglia and astrocytes after DTX treatment showed that their proliferation was only observed at time points significantly later than the development of neuropathic symptoms. 81 These findings suggest that neither microgliosis nor astrogliosis play a role in mediating central pain provoked by ablation of oligodendrocytes. Although this represents an interesting finding of central neuropathic pain being induced independent of immune reactions, it is unclear how axonal pathology relates to changes in pain perception.
A study by Zarpelon and colleagues 82 demonstrated the role of oligodendrocyte-derived IL-33 in the development of neuropathic pain. IL-33 production was increased after spinal cord chronic constriction injury (CCI) of the sciatic nerve in the mice, contributing to enhanced CCI hyperalgesia, whilst oligodendrocytes were identified as the main cells expressing IL-33 within the spinal cord.
Interaction between microglia and mast cells
An additional exciting avenue that has been explored is the relationship between microglia and mast cells. Studies show that activated mast cells undergoing degranulation can release factors that sensitise nociceptors, thereby directly contributing to neuropathic pain. [83] [84] [85] Mast cells can migrate through the BBB, but also through the blood-spinal cord barrier, both in normal circumstances and disease states. 86 Observations that both cell types are frequently involved at similar sites after nerve injury or inflammation 87 has led to speculation as to whether mast cells and microglia may operate in tandem to contribute to inflammatory pain. Indeed, there is evidence suggesting that lines of communication do exist. Zhang and colleagues 88 demonstrated that mast cell tryptase stimulated microglia activation and subsequently produced pro-inflammatory factors TNF-a and IL-6, via protease-activated receptor 2 (PAR-2) signalling. This was confirmed by the observed reduction in tryptaseinduced TNF-a and IL-6 production, and suppression of microglial p38 MAPK pathway, after PAR-2 inhibition. 88 Combining these findings with evidence that demonstrates microglial activation via P2X4 purinoceptors and downstream p38 MAPK pathway causing BDNF release, 89 has led to the development of a notion that suggests a putative unifying mechanism for pain hypersensitivity based on microglia-mast cell interaction. This mechanism involves mast cell tryptase-mediated activation of PAR2 on microglia, resulting in microglial TNF-a and IL-6 production, and P2X4 receptor up-regulation causing BDNF release. 87 Yet again, though, these postulated mechanisms and observations regarding mast cell involvement need further validation in order to fully understand the overall extent to which they contribute to the development of neuropathic pain.
Interaction between microglia and T cells
There is accumulating evidence to suggest that T-cell dependent mechanisms, in particular involving CD4þ T-cells, are also integral to the development of neuropathic pain. Studies have shown that CD4þ T-cells can infiltrate the dorsal spinal cord after peripheral nerve injury and, thus, contribute to the evolution of allodynia, a feature typical of neuropathic pain states. 90 91 It has also been observed in animal studies that a lack of functional T-cells results in a phenotype displaying reduced tactile allodynia. 92 This situation was reversible by transfer of splenic CD4þ T-cells from neuropathic animals. 92 Attempts to further delineate the action of CD4þ T-cells, has once again revealed that communication with microglial cells is a fundamental element in maintaining a neuropathic pain state. Zhang and colleagues 93 examined the importance of the enzymatic activity of cathepsin S, a protease involved in the activation of CD4þ T-cells, in a peripheral nerve injury model, where cathepsin S was inhibited through either genetic deletion or pharmacological inhibition. In addition to significantly reducing mean paw withdrawal threshold and suppressing the injury-induced increase in splenocytes observed in control mice, cathepsin S deficiency attenuated the proliferation and mean number of microglia 14 days after nerve injury. 93 Furthermore, the authors demonstrated via immunohistochemistry that phosphorylated STAT1, a molecule downstream of interferon-gamma (IFN-c) receptor activation, was markedly increased exclusively in Iba1-positive microglia in wild-type mice after peripheral nerve injury, but not in cathepsin S deficient mice. 93 Thus the authors postulated that the activity of cathepsin S after peripheral nerve injury leads to antigenspecific activation of CD4þ T-cells, which then infiltrate the spinal cord to activate microglia via IFN-c signalling, thus causing the transition to, and maintenance of, a chronic pain state, demonstrated by persistent nociceptive symptoms such as hyperalgesia and allodynia. The importance of IFN-c receptor signalling has also been highlighted in other studies. Tsuda and colleagues 94 demonstrated that stimulation of IFN-c receptors in spinal microglia caused activation of microglia and longlasting allodynia. More specifically, after intrathecal IFN-c administration, an increase in phosphorylated STAT1 was only seen in cells exhibiting the microglial marker OX-42, and not in GFAP-marked cells. By day three, both an increase in the number of microglia and morphological changes suggestive of microglial activation were observed. 94 Conversely, mice lacking IFN-c receptors showed significant attenuation of peripheral nerve injury-induced activation of spinal microglia and tactile allodynia. Interestingly, infusing microglia expressing IFN-c receptors into deficient mice reversed this. 94 Taken together, CD4þ T-cells and IFN-c signalling may be crucial links within the overall neural immune system that influence microglial activation and, as such, may represent a target for novel therapies.
Other studies have suggested alternative mechanisms by which CD4þ T-cells may behave. Taking the observation that microglia, when activated, express elevated concentrations of CD40, 95 in combination with earlier evidence suggesting that elevated CD40 expression correlates with other CNS diseases including Alzheimer's disease and multiple sclerosis, 96 97 Cao and colleagues 98 hypothesised that CD4þ T-cells infiltrating the spinal cord after spinal nerve injury communicate with microglia via CD40 interaction. This was shown to be a potentially viable mechanism of action, as CD40 knockout mice displayed significant attenuation in mechanical hypersensitivity from day five post L5 nerve transection surgery compared with wild type control mice, although notably there was no significant difference at day one post surgery, 98 therefore implying that the key role of microglial CD40 may be in the maintenance of a neuropathic pain state, rather than its initiation.
Targeting microglia as a therapeutic strategy in treating neuropathic pain Current treatments for neuropathic pain, such as tricyclic antidepressants or opioids, do not target the underlying mechanism and thus often provide transient pain relief, but only in a minority of patients. However, by elucidating the mechanism of activation of microglial cells, and the effect of pro-inflammatory cytokines released by microglial cells, new targets for neuropathic pain treatment are identified. One drug being studied as a potential therapy for neuropathic pain is minocycline. Minocycline is a tetracycline that has been in use as an antibiotic for more than 30 yr. 99 Mei and colleagues 100 found that minocycline was effective in preventing the development of neuropathic pain by inhibiting microglial cells, when the drug was given before the nerve injury. Zanjani and colleagues 44 also investigated the effect of minocycline, and found that minocycline prevents the development of hyperalgesia and allodynia, though it is not effective against existing hyperalgesia and allodynia. Also, Zanjani and colleagues 44 discovered a decrease in IL-6 concentrations in mice treated with minocycline, which may contribute to the reduction in hyperalgesia and allodynia. Minocycline is also shown to reduce MMP-2 and MMP-9. 24 This combination of decreasing the activation of microglial cells, and targeting specific cytokines involved in both the development and persistence of neuropathic pain, makes minocycline a promising potential treatment. Inhibitors of other cytokines or antagonists of receptors, such as the CCR2 and TNFR receptors, may also be worthy of further investigation. However, there are a wide range of factors involved in the development and maintenance of neuropathic pain and the role of each individual component, and their interaction with other pain mediators, has not been elucidated. As a result, targeting specific cytokines may not be an efficient treatment for neuropathic pain. There is evidence that different cytokines fulfil different roles in developing neuropathic pain. Inhibiting a specific cytokine can result in a delay in neuropathic pain or a reduction in symptoms, although blocking a specific cytokine does not consistently result in blocking all of the pain for an extended period of time. Therefore, effective treatment for neuropathic pain must target multiple causative factors, and target the different phases of neuropathic pain, as the mediators present differ over time. Risk factors should be identified to be able to give patients preventative treatment, such as preoperative minocycline. Along with minocycline, animal studies have been conducted to investigate the role of prostaglandin E2 (PGE2), a proinflammatory prostanoid, in mediating neuropathic pain via its four PGE receptor subtypes, EP1-EP4, and spinal microglial activation. 101 It was found that mice deficient in microsomal prostaglandin E synthase-1 had impaired microglial activation, whilst there was also an inhibition of the spinal NMDA-nitric oxide cascade and subsequent blockade of mechanical allodynia, after peripheral nerve injury. Similarly, intrathecal administration of indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), and EPI antagonists, resulted in a significant attenuation in mechanical allodynia and reduction in microglial activation. Overall, there is in vivo evidence to suggest that PGE2 is responsible for the activation and maintenance of neuropathic pain by activating spinal neurones, and retaining microglia at the central terminals of primary afferent fibres via EP1/2-mediated nitric oxide production. Although it remains to be elucidated whether NSAIDs possess a beneficial effect in patients with neuropathic pain, it is interesting to note that the analgesic effect of NSAIDs directly correlates with the concentration of PGE3 in cerebrospinal fluid (CSF). A clinical trial in patients with chronic pain demonstrated that ketorolac, an NSAID, significantly reduced pain intensity in patients with high concentrations of CSF PGE2, but had no beneficial effects in those with normal concentrations. 102 As NSAIDs seem to only have beneficial effects in a certain subset of patients, the routine use of NSAIDs in the management of neuropathic pain is unadvised, whilst monitoring of CSF-PGE2 in patients with neuropathic pain seems problematic and tedious. There is also evidence to suggest that intrathecal microRNA-124 treatment may be a promising, novel therapy to prevent and treat persistence neuropathic pain. 103 The microRNA, miR-124, is thought to be responsible for maintaining neuronal microglia in a quiescent state. Microglial concentrations of the G protein-coupled receptor kinase (GRK2) is reduced in models of chronic pain, with persistent hyperalgesia demonstrated in GRK2 deficient mice. The administration of intrathecal miR-124 has demonstrated the ability to modulate concentrations of GRK2, and potentially be a promising therapy for pathological chronic pain associated with persistent microglial activation. Animal models have been developed to study peripheral nerve injury and neuropathic pain. The most common model is the chronic constriction injury model, usually involving the sciatic nerve. 4 Other models include partial nerve ligation, complete nerve ligation and spared nerve injury. 4 However, different models result in different temporal release of mediators, making it difficult to compare research using different models. Furthermore, this suggests that not all forms of nerve injury result in identical neuropathic pain. Many of the studies mentioned observe the relationship between certain factors and pain. These studies focus on inducing neuropathic pain by administering a mediator or preventing neuropathic pain by inhibiting a certain factor. These studies often do not elucidate the mechanism by which a certain factor can interact with neurones to result in neuropathic pain, which is important for treating the underlying mechanisms to provide long-term pain release. Therefore, there are clear difficulties in translating preclinical findings into clinical practice. Behavioural testing is a commonly used method to investigate pain response in animals. At present, assessment of pain in murine models primarily relies on observation of simple reflex responses elicited by thermal, mechanical or chemical stimuli. 104 105 In response to the stimulus, pain sensation begins in receptors in the skin and viscera. These receptors predominantly project to the dorsal horn of the spinal cord, where afferent neurones carrying nociceptive information from the periphery converge onto projection neurones or interneurons. Subsequently, interneurons are involved in excitatory or inhibitory modulation within the dorsal horn and projection to nociceptive centres in the brain. After peripheral nerve injury, microglia in the spinal cord are activated and undergo significant morphological transformation from ramified to amoeboid, increased expression of microglial markers, including CD11b and IBa1, and proliferation within the spinal cord. 9 Nerve ligation is one of the most commonly used methods to induce chronic neuropathic pain, which involves surgery in order to obliterate specific spinal or peripheral nerves to induce a neuropathic pain phenotype. 106 107 For example, ligation of S5 and S6
spinal nerves confers consistent heat hyperalgesia, and allodynia induced after cold or mechanical stimuli, whilst inadvertent damage to S4, causes significant visible neurological deficit including paralysis; this acts as a robust safeguard against incorrect ligation. 106 An exhaustive number of nerve ligation models exist, including axotomy, chronic constriction surgery, spared nerve ligation and excitotoxic spinal cord injury models, each with their own combination of advantages and disadvantages. In terms of quantifying and detecting neuropathic pain behaviour in animals, the von Frey test is the most commonly used method. This test involves the use of a thin flexible filament to the skin, applied with just enough force to induce a bend in the filament. 108 Although the von Frey test itself is not painful, it is used to detect cutaneous mechanical hyperalgesia by applying mechanical stimuli to the plantar surfaces of the hind-paws. [108] [109] [110] This allows the quantification of neuropathic pain behaviour, hyperalgesia and efficacy of analgesics. It is important to note that, in recent yr, more refined tools to assess neuropathic pain behaviour after spinal cord injury have been developed, such as the Randall-Selitto test, which has been used in a number of studies to evaluate inflammatory pain responses. 
